Ad
Tuesday, 9 May 2017
Pfizer immuno-oncology drug wins U.S. approval for bladder cancer
(Reuters) - U.S. health regulators on Tuesday granted accelerated approval for Pfizer Inc's immuno-oncology drug Bavencio to treat advanced bladder cancer, marking the second approval in less than two months for the treatment developed along with Germany's Merck KGaA.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment